Donanemab, another anti-Alzheimer's drug with risk and uncertain benefit
Poul Flemming Høilund‐Carlsen, Abass A. Alavi, Jorge R. Barrio, Rudolph J. Castellani, Tommaso Costa, Karl Herrup, Kasper P. Kepp, Rachael L. Neve, George L. Perry, Mona-Elisabeth R. Revheim, Nikolaos K. R K Robakis, Stefano Luca Sensi, Bryce Vissel
The abstract is not reproduced here because its license does not permit redistribution. Read it at the original source.
Record
- Archive ID
- doi:10.1016/j.arr.2024.102348
- Published
- Jun 1, 2024
- Venue
- Ageing Research Reviews
- DOI
- 10.1016/j.arr.2024.102348
- PubMed
- 38830549
- Categories
- Alzheimer's disease research and treatments
- License
- cc-by-nc-nd
- Provenance
- openalex